

BY HAND

The Board of Directors
Shanghai Henlius Biotech, Inc.
11F, Building B8
188 Yizhou Road
Xuhui District
Shanghai, PRC

3 December 2025

Dear Sir or Madam,

**Re: Shanghai Henlius Biotech, Inc. (the “Company”) –
CONTINUING CONNECTED TRANSACTIONS
RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION
(the “Transaction”)**


We refer to the circular of the Company dated 3 December 2025 (the “Circular”) in connection with the Transaction. Capitalised terms used in this letter shall have the same meaning as those defined in the Circular unless otherwise specified.

We hereby give our consent, and confirm that we have given and have not withdrawn our written consent to the issue of the Circular with the inclusion of our letter or opinion addressed to the Independent Board Committee issue and the Independent Shareholders (the “**IFA Letter**”) and references to our name in the form and context in which they are included in the Circular.

We also confirm that as at the Latest Practicable Date, (i) we did not have any interest, either direct or indirect, in any assets which had been, since 31 December 2024, being the date to which the latest published audited financial statements of the Company were made up, acquired or disposed of by or leased to any member of the Group or are proposed to be acquired or disposed of by or leased to any member of the Group; and (ii) we did not have any shareholding interests in any member of the Group and we did not have any right, whether legally enforceable or not, to subscribe for or nominate persons to subscribe for securities of any members of the Group.

We hereby consent to this letter and the IFA Letter being made available for public inspection as described in the Circular.

Yours faithfully,
For and on behalf of
Rainbow Capital (HK) Limited


Name: Dany Leung
Title: Managing Director